ACTRN12620000840987招募中1 期
Phase I trial on safety and tolerability of bone-marrow derived mesenchymal stromal cells (MSC) for deteriorating COVID-19 pneumonia
Royal Perth Hospital Cell & Tissue Therapies WA0 个研究点目标入组 10 人开始时间: 2020年8月26日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Confirmed bi-lateral pneumonia on chest X-ray
- •Confirmed COVID-19 infection
- •Worsening hypoxia with an increasing oxygen requirement by 2L/min (Hudson mask or nasal prongs) to maintain SaO2>92%, measured on 2 occasions over >2 hours or requiring more than 4L/min to maintain SaO2>92% with no history suggestive of chronic hypoxia.
- •Planned for active treatment with goals of care category A, B or C, including those not eligible for ICU transfer.
排除标准
- •Life expectancy < 48 hours or GOPC D (palliation only).
- •Any condition that in the opinion of the investigator may interfere with the safety of the patient or evaluation of study objectives.
- •Unable to provide consent.
- •Recent therapy within the last 3 months with immunomodulatory agents including monoclonal antibodies and anti-neoplastics.
- •Age <18 years
- •Enrolled in another interventional trial.
研究者
相似试验
招募中
不适用
To Assess the Safety and Pharmacokinetic Profile of CKD-516 inj. Administered on A Twice-Weekly Schedule in Patients with Advanced Solid Cancers Failed to Standard TherapyNeoplasmsKCT0000499Chong Kun Dang24
已完成
不适用
A Study to Evaluate Safety and Pharmacokinetic Characteristics after Administration of the SJP003 in Healthy Male VolunteersEndocrine, nutritional and metabolic diseaseKCT0004019Samjin Pharmaceutical40
已完成
1 期
A trial to test the safety of a herbal formulatioCTRI/2018/02/011689SK Biolabs100
已完成
1 期
A trial to test the safety of a herbal drug.CTRI/2017/11/010617SK Biolabs100
已完成
1 期
A clinical trial to test the safety of a drugCTRI/2017/11/010540SK Biolabs100